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ABSTRACT 
 
Genetics of Holoprosencephaly (HPE), a congenital malformation of the developing human 
forebrain, is due to multiple genetic defects. Most genes that have been implicated in HPE 
belong to the Sonic Hedgehog (SHH) signaling pathway. Here we describe a new candidate 
gene isolated from array CGH redundant 6qter deletions, DELTA Like 1 (DLL1), which is a 
ligand of NOTCH. We show that DLL1 is co-expressed in the developing chick forebrain 
with Fgf8. By treating chick embryos with a pharmacological inhibitor, we demonstrate that 
DLL1 interacts with FGF signaling pathway. Moreover, a mutation analysis of DLL1 in HPE 
patients, revealed a three-nucleotide deletion. These various findings implicate DLL1 in early 
patterning of the forebrain and identify NOTCH as a new signaling pathway involved in HPE. 
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INTRODUCTION 
Holoprosencephaly (HPE) is the most common congenital malformation of the developing 
human brain. It is characterized by defective division of the forebrain into distinct left and 
right hemispheres (1). The clinical spectrum of HPE includes a broad range of malformations 
of the brain and face. In the most severe form (alobar HPE), the forebrain consists of a single 
ventricle, and the midline structure is missing; in semi lobar forms, the frontoparietal lobes 
are fused and the interhemispheric fissure is present posteriorly; in lobar HPE, a distinct 
hemispheric fissure is present; in microform HPE, the least severe form, midline structures 
are present and only mildly affected. 
The etiology of HPE is highly heterogeneous and complex, presumably involving numerous 
genes and environmental factors. Chromosome aberrations have provided an important clue 
for the initial location of genes involved in HPE (2). From karyotype analyses, various 
genomic regions have been described as containing HPE candidate genes. Candidate genes 
namely SHH, SIX3 TGIF and ZIC2 (3-7) have been identified in these loci. Mutations or 
deletions in these main genes account for about 28% of cases, and all cases are heterozygous 
(8-10). Other genes, belonging to brain development pathways, like Hedgehog or Nodal, were 
then tested for mutations and subsequently validated for HPE: NODAL, TDGF1, FOXH1, 
PTCH1, GLI2, DISP1 (11-14). However, mutations or deletions in these genes occur 
infrequently and are generally associated with HPE microforms (4). 
The phenotypic variability of HPE patients with particular gene mutations cannot currently be 
explained by single-gene haploinsufficiency. However, a multihit hypothesis would be 
consistent with the variable penetrance of familial mutations associated with this disease. 
HPE might result from two or more independent genetic lesions impacting forebrain 
formation. Indeed, the detectable mutations in HPE genes observed in patients may represent 
only one of several discrete steps needed to produce this abnormality. 
 4 
The forebrain consists of several functionally and morphologically distinct structures. It 
acquires its regional specialization under the influence of several patterning centers that are 
recruited as early as the gastrulation stage (2). In the developing prosencephalon, opposed 
ventralizing and dorsalizing activities of Hedgehog (HH) and Bone Morphogenetic Protein 
(BMP) signaling pathways have key roles in the specification of dorso-ventral polarity (15). 
In addition to SHH signaling, FGF is required to elicit full specification of the ventral 
telencephalon. The involvement of FGF during midline development has been demonstrated 
by detailed observations of telencephalic conditional FGF receptor mice (16). Therefore, 
partition of the forebrain and formation of the midline require delicate balance between SHH 
and FGF signaling. 
We previously performed genome-wide screening for microscopic anomalies in our HPE 
cohort using comparative genome hybridization arrays (17). Seventeen % of the HPE patients 
tested displayed de novo microrearrangements, demonstrating the high prevalence of genomic 
imbalances in cases of HPE and strongly supporting the notion of a multigenic origin of this 
developmental disorder. Here, we report four redundant chromosomal deletions overlapping 
the 6qter region in unrelated patients suffering severe HPE or microforms. Bioinformatics 
investigations of on this region allowed us to define a minimal critical deleted region of 
2.2 Mb, containing a pertinent candidate gene, DLL1. DLL1 is a ligand of NOTCH and is 
consequently a major actor in many developmental processes (18). Although NOTCH 
signaling has been described to be important during the neurogenic phase of forebrain 
development (19), no link to HPE has previously been described. Here, we provide the first 
evidences that DLL1 haploinsufficiency contributes to HPE. 
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RESULTS 
 
Microarray analysis and determination of the break point  
We used array-CGH to identify microrearrangements. The Agilent Human genome CGH 
array (Agilent Technologies, Santa Clara, CA, USA) used for patients 1, 2 and 3 has been 
described previously (17). Patient 4 was tested with the same Agilent CGH array but with the 
105K microarray. 
Patient 1 displayed a large hemizygous deletion of 15.7 Mb from 6q24 to the terminal end 
(table 1 and Fig. 1). This deletion was initially detected by MLPA and confirmed with the 
44K oligonucleotide Agilent Array. According to the NCBI map viewer, this region 
encompasses 82 genes. No notable findings were observed in any other region except for 
copy number variations (CNV). FISH analysis of the parents showed that they did not have 
this deletion and thus proved de novo occurrence. 
Patient 2 displayed a hemizygous deletion of 12.3 Mb (Table 1 and Fig. 1) from 6q25.3 to the 
telomere. No other chromosomal abnormality was observed. 
Patient 3 displayed a hemizygous deletion of 5.2 Mb from 6q26 to the terminal end (Table 1 
and Fig. 1) encompassing 37 genes. This deletion was associated with an 8 Mb duplication of 
20p-ter.  
Patient 4 displayed a hemizygous deletion of a maximum size of 2.2 MB from 6q27 to the 
terminal end involving 14 genes (Tables 1,2 and Fig. 1). Parental FISH analysis showed no 
evidence of a similar loss in either of the parents. 
 
DLL1 is ranking first by Gene prioritization 
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The region deleted from patient 4 (168,690,655-170,899,992) was 2.2 Mb long and includes 
14 RefSeq as listed in the University of California Santa Cruz (UCSC) Genome browser 
(Table 2). None of the 14 genes that map in this region has previously been clearly associated 
with a human brain disorder. Ten have no pathological findings associated with them, five 
have no annotation in OMIM, and four are open reading frames that are not annotated at all. 
We used the prioritization software Endeavour (20) to identify candidate genes. We listed the 
10 known HPE genes as a reference set: SHH, SIX3, ZIC2, TGIF, GLI2, TDGF1, FOXH1, 
NODAL, PTCH1 and DISP1 (4). The information available for each of the 10 annotated genes 
within the 2.2 Mb deletion was then compared with these reference set. The DELTA-LIKE 1 
(DLL1) gene was identified as the highest priority gene, which is not surprising as it is the 
only gene associated with developmental processes amongst the 10 genes. 
Consequently, we have extended the application of Endeavour software to the 37 genes 
mapping in a larger region of 7.2 Mb encompassing the 2.2 Mb deleted region. Indeed, 
genomic deletions can contribute to phenotypic differences by modifying not only the 
expression levels of genes within the aneuploid segments but also of neighboring, normal 
copy-number genes (21). This position effect has been reported as far as 5 Mb away from the 
breakpoints. The DLL1 gene was again identified as the highest priority gene in this extended 
region. 
 
Molecular screening of the DLL1 gene in HPE patients: identification of a 3 bp-deletion  
We systematically sequenced the eleven exons and flanking intronic regions of the DLL1 
gene from each of 100 HPE probands of our cohort (17). A heterozygous 3-bp deletion 
affecting two codons (NM_005618.3:c.1802_1804del) was identified in exon 9 from a patient 
with semilobar HPE (Fig. 2). The mutation was inherited from the father who underwent 
septoplasty of the nasal septum but did not display obvious typical form of HPE. It leads to 
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the substitution of two amino-acids (aspartic acid and isoleucine) by one valine 
(p.Asp601_Ile602delinsVal). Both substituted aminoacids are conserved through seven 
species from Xenopus to mammals (Fig. 2), and map within an ubiquitin motif in the 
intracellular domain of DLL1 (22). This mutation was not found in 103 ethnically matched 
controls. Furthermore, it was not detected in the pilot data from the 1000 Genomes Project 
(http://www.1000genomes.org) and not reported as a common variant in the Alamut software 
(Interactive Biosoftware). 
 
Expression of Dll1 during early development of the chick forebrain is coincident with 
sites of FGF signaling 
We studied the expression pattern of Dll1 and in particular whether it is expressed in areas of 
the forebrain that are abnormal in cases of HPE. The dynamic expression of Dll1 during 
somitogenesis has been well described (23, 24), but less is known about its expression in the 
forebrain at the stage of HPE development. We used whole-mount in-situ hybridization to 
study the expression patterns of Dll1 from gastrulation to stage HH14 (anlagen of the optic 
vesicle) in chick embryos (Fig. 3). Dll1 was first detected at the onset of gastrulation (HH5), 
in the extending head fold, and then the level of expression rapidly increased as the cranial 
neuropore closes (Fig. 3a, c-e). At HH10, the anterior neuropore is closed and the 
prosencephalon has been formed. Subsequently, as the optic vesicles begin to invaginate, Dll1 
was clearly detected in the cranial neuropore. In situ hybridization for Dll1 revealed a strong, 
well-defined domain that extended from the most anterior facial region to the anterior 
boundary of the eye and covered the rostro-ventral portion of the prosencephalon (Fig. 3e). In 
older embryos, transcripts persisted in the ventral developing head (Fig. 3i). Interestingly, a 
similar pattern of expression has been reported for Fgf8 in the head process (25). However, 
unlike Dll1, Fgf8 expression is not detected at stage HH5 in the extending head fold but 
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appears in the anterior neuropore at HH8 (Fig. 3b). At stage 10, Fgf8 and Dll1 are similarly 
expressed in the rostro-ventral portion of the prosencephalon. To determine whether Dll1 and 
Fgf8 are expressed in the same tissue, we performed in situ hybridization for both Fgf8 and 
Dll1 on consecutive histological sections at HH11 (Fig. 3e-h). Transcripts of both genes were 
found in the surface ectoderm and neurectoderm in histological sections. 
The observed expression pattern of Dll1 closely coincides with known sites of Fgf8 
expression in the anterior region of chick embryo (25) in which FGF signaling plays a key 
regulator function during anterior forebrain development (26). 
 
FGF signaling is required to maintain Dll1 expression in the telencephalon  
FGF signaling, like SHH signaling, is essential for the generation of ventral cell types in the 
telencephalon. We therefore investigated whether FGF signaling had a role in regulating the 
expression of Dll1. We developed a drug-based strategy that allowed us to block endogenous 
FGF signals from the onset of gastrulation. SU5402, is an efficient in vitro pharmacological 
inhibitor of FGFR (27) and as proved to be a useful reagent for reducing FGF signaling 
activity in vivo (26). Therefore, we developed a protocol to use SU5402 to block FGF signals 
in chick whole embryos from the onset of gastrulation (HH4) to the primary regionalization of 
the forebrain (HH12). 
We first tested a variety of concentrations to determine the maximal dose that allows head 
development. We treated embryos with SU5402 for periods of 24 hours from pregastrulation 
stages (HH4) to the 16 somites stage (HH12). We observed that 100 % (n = 23/23) of the 
embryos treated with a concentration of 10 !M SU5402 showed severe morphological defects 
all along the antero-posterior axis with anterior truncation as previously described in 
Zebrafish (26, 28). These defects were in all cases associated with substantial down-
regulation of Dll1 expression in the anterior neuropore (Fig. 4b) and a posteriorization of the 
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Dll1 signal in the presomitic mesoderm. Since this down-regulation of Dll1 may be linked to 
the severe phenotype of the treated-embryos, we have used a lower concentration of SU5402. 
In contrast, this treatment (5 !M of inhibitor) gave milder defects: no anterior truncation was 
observed and the embryonic axis was normal, as shown by the normal expression of Dll1 in 
the presomitic mesoderm (Fig. 4c). Interestingly, Dll1 expression was still very substantially 
reduced in 50 % (11/22) of the embryos, and lower than normal in the other 50% (Fig. 4c). 
This suggests that FGF signaling is important to maintain Dll1 expression in the anterior 
neuropore. 
 
Inhibiting SHH signaling does not disrupt Dll1 expression in the anterior neuropore 
We next tested whether perturbations of SHH signaling disrupted Dll1 expression in the head 
level. To block SHH signaling, chick embryos were cultured in the presence of cyclopamine, 
a plant-derived steroidal alkaloid cyclopamine. Cyclopamine directly antagonizes the SHH 
signal activation component Smoothened (29). The drug was applied at HH4 (before the onset 
of gastrulation) at a concentration of 5!M (30). At this dose, cyclopia was observed in 100% 
of the treated embryos (n=27) and there was no noticeable effect on Dll1 expression in the 
prosencephalon (Fig. 4d). Thus, we conclude that Dll1 expression in the early prosencephalon 
is not regulated by SHH signaling. 
 
 
DISCUSSION 
 
The inheritance of HPE is complex and results from interplay between multiple genetic 
factors (2, 31). Discovery of new causative genes for such defects in human is challenging 
because of genetic heterogeneity and variable penetrance. In view of these complexities, we 
used an integrated human genetic approach and an appropriate animal model to study genetics 
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of HPE. This strategy allowed us to describe a new risk locus for HPE in 6qter that contains 
an excellent candidate gene, Dll1. We also provide experimental data linking this gene with 
HPE syndrome. 
In a previous array-CGH study we demonstrated the high prevalence of rearrangements in 
HPE patients (4, 17). Here, we describe rearrangements in overlapping regions in four 
patients leading us to focus on a hemizygous deletion in the qter extent of the long arm of 
chromosome 6 (6qter), common to these four cases. In a context of a rare disease, this rate of 
6qter deletion is very significant. 
Rare cases of abnormalities of the terminal long arm of chromosome 6 have been reported in 
the literature, most having been revealed by standard cytogenetic analysis and most in live 
born children. The 6qter deletion syndrome has various characteristic features including 
mental retardation, facial dysmorphism, seizure and brain abnormalities, including dysgenesis 
of corpus callosum (32, 33). These cases may represent microforms of HPE (34). Some 
cardiac and ophthalmic abnormalities have also been reported but were mostly associated 
with very large 6q deletions (35). 
 
The deletions in our four patients were of between 15.7 Mb and 2.2 Mb. There is no evident 
correlation between the size of the deletions and the HPE severity; indeed, both the 12.3 Mb 
deletion and the smallest deletion of 2.2 Mb were associated with alobar HPE, the most 
severe form. Such heterogeneity is a common feature in HPE; it has been extensively 
described for patients with alterations in the SHH, the main gene in HPE (36, 37). This 
contributed to our suspicion that only one gene within the region deleted in our four patients 
was responsible for HPE. We therefore assumed that the minimal deleted region of 2.2 Mb, 
extending from nucleotide 168,690,655 to 170,899,992 of 6qter, contained a novel HPE gene. 
This deleted region contains 14 genes and Endeavour was used to prioritize them (20). This 
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analysis identified Delta-like 1 (DLL1) as the best candidate gene. We also tested for a long-
range effect of the minimal deletion, by including the 5 Mb flanking the minimal region (21) 
and nevertheless, DLL1 was persistently the best candidate. DELTA proteins function as cell-
surface ligands for NOTCH receptors in a highly conserved signal transduction mechanism. 
Most importantly, the NOTCH plays a role in patterning various tissues during embryonic 
development. 
Of the other genes present in this region, TBP is a potential candidate gene. TBP encodes the 
TATA-binding protein, which is a general binding transcription factor and it has been 
reported to be a good candidate for mental retardation (38). However, TBP was not scored 
highly by Endeavour in our analysis and no relation with brain development has been 
attributed to this gene by explorations with mutant mice (39).  
 
Although we cannot formally exclude the possibility that haploinsufficiency of other 6qter 
genes contributes to the phenotype, the identification of a 3-bp deletion in a highly conserved 
region within the DLL1 gene in an independent case of HPE is strong support for 
haploinsufficiency of this gene participating in the HPE phenotype. This 3-bp deletion, 
leading to the substitution of two aminoacids (aspartic acid and isoleucine) by a valine, is not 
reported as a common variant in the Alamut software. All Notch ligands share a similar 
architecture: an N-terminal region required for receptor binding, a Delta/Serrate/lag-2 domain, 
a variable number of EGF like repeats, a transmembrane segment and a relatively short 
cytolasmic tail (40). The 3-bp deletion maps within a putative ubiquitin motif in the 
intracellular domain of DLL1 (22). Notably, it has been shown that ubiquitination of Notch 
ligands is essential for effective Notch activation (41-43). Additionally, this deletion 
implicates aminoacid residues that are conserved through species from Zebrafish to 
chimpanzee, consistent with this variant having functional significance (Fig. 2). 
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That the father of the patient carrying the 3-bp deletion transmitted the mutation but did not 
display patent HPE is not surprising in view of the incomplete penetrance of the disease. 
Indeed, the majority of HPE mutations are inherited and variable expressivity among HPE 
family members is characteristic of this pathology (10). It indicates that additional factors 
contribute to the severity of the phenotype (2). One significant mutation of Dll1 was found in 
a series of 100 HPE patients. Similar findings have been described for several HPE genes, in 
fact, mutations of the TDGF1, DISP1, GLI2, NODAL, FOXH1 or PTCH1, collectively 
explain 1% of the studied cases and are often associated to microforms (44). 
 
We report here that Dll1 is expressed during the first stages of brain development consistent 
with it having a role in forebrain development. We provide the first detailed description of 
Dll1 expression in the developing forebrain and show that it corresponds to known sites of 
FGF signaling. Dll1 is transiently expressed during forebrain formation in a spatially and 
tissue-restricted manner at a critical period of forebrain development. Expression of Dll1 in 
the head region was first detected in head fold-stage embryos in the presumptive forebrain 
and high levels of Dll1 transcripts did accumulated in the telencephalon at the time of anterior 
neuropore closure. From this stage, the pattern of Dll1 expression in the forebrain is 
remarkably similar to that of Fgf8 in the anterior neuropore. 
FGF signaling, like SHH signaling, is essential for the generation of ventral cell types in the 
telencephalon. Telencephalon phenotypes in various animal models attributed to reduced FGF 
activity include midline defects (28, 45). Moreover, there is evidence that FGFs act in a dose-
dependent manner to pattern the ventral telencephalon (46). Most significantly, heterozygous 
microdeletions and mutations affecting FGF8 have been described in HPE cases, implicating 
the FGF signaling pathway in human HPE (47, 48). 
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The overlapping expression patterns of the Dll1 and Fgf8 genes suggest an interaction 
between these two signaling pathways. To test this possibility, we used a pharmacological 
approach to inactivate FGF signaling and examine the consequences for Dll1 expression. We 
exploited ex ovo chick embryo cultures (so called roller cultures) to test the effects of 
inhibition of the FGF signaling during brain formation. Reducing FGF signaling by SU5402 
treatment during early brain development totally inhibited Dll1 expression specifically in the 
severely disorganized telencephalon. At lower concentration of inhibitor, while the 
telencephalon is not truncated expression was still down regulated in the anterior neuropore. 
These observations suggest that FGF signaling is required to maintain (49) the expression of 
Dll1 in the telencephalon. However, the onset of Fgf8 expression is around the 4-somite stage 
(HH8), whereas Dll1 expression is detectable before the head-fold stage (HH5). Thus, it is 
unlikely that Fgf8 initiates Dll1 expression in the head process as Dll1 is expressed first in 
this tissue. 
As the most frequent cause of holoprosencephaly is lack of SHH signaling, we also examined 
the expression of Dll1 in a hedgehog-deficient chick model. The findings that Dll1 expression 
was normal suggest that this gene is not regulated by SHH signaling pathway.  
The evolutionarily conserved NOTCH signaling in vertebrates is thought to act predominantly 
in a ligand/receptor–like manner and mediate various cell-fate decisions important for the 
morphogenesis and development of numerous organs (18). As a result, the molecular 
mechanism of this pathway has been the subject of intensive research (19). Interestingly, 
DLL1-NOTCH signaling interacts with FGF signaling during the clock mechanism process to 
regulate Hes7 leading to the formation of somites (49). Also, FGF signaling is required for 
expression of Dll1 in the spinal cord stem zone (50). These various findings support the 
existence of an interaction between Fgf8 and of Dll1 to cooperatively regulate ventral 
telencephalon patterning. 
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However, the function of DLL1 during forebrain regionalization is still unclear. Dll1 mouse 
mutants die around day 11; although some midline defects have been observed, no typical 
HPE phenotype has been described (51, 52). Moreover, Dll1 haploinsufficiency in adult mice 
leads to a reduce body weight (53) Nevertheless no investigations of possible fine structural 
abnormalities of the forebrain have been done. Targeted mutations of the Notch1 or Notch2 
gene give rise to widespread cell death and result in embryonic death around E10.5 (54-56). 
Interestingly, telencephalic-specific deletion of Notch1 results in a reduction in the size of the 
ganglionic eminence, a ventral structure of the forebrain (57). While these animal models 
strongly implicate a perturbation of the NOTCH signaling pathway in the onset of HPE, it 
also demonstrate that mutation in Dll1 has a modest deleterious functional effect on the brain. 
Therefore, it is reasonable to conclude that additional genetic or environmental factors, 
presently unknown, would be required to produce severe HPE. In fact, although the number 
of instances is small, some cases of HPE are the result of two or more independent genetic 
lesions impacting common or interacting developmental pathways during forebrain 
development (58). It is therefore likely that our patients carry other deleterious mutations. 
However no co-morbid alterations have been identified to date. In a forthcoming study, a 
whole exome sequencing of these cases would provide evidence for this hypothesis. 
In conclusion, our data demonstrate that dysregulation of DLL1 confers susceptibility to the 
occurrence of HPE. Therefore, DLL1 is another of the large set of genes that, when 
structurally altered, can lead to HPE disorders. Most importantly, this study provides evidence 
for a role of the NOTCH signaling pathway in early forebrain development that is linked to 
the FGF signaling pathway. Future directions should be centered on screening genetics 
elements of the NOTCH pathway in HPE patients. 
  
MATERIALS AND METHODS 
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Patient reports 
Patient 1: The proband was a female foetus diagnosed with semi-lobar HPE. No familial 
history has been noted, although there were two previous first-trimester miscarriages. 
Termination of pregnancy occurred at week 14 of gestation in a context of intrauterine growth 
restriction. Anatomopathological examination confirmed semi-lobar HPE with complete 
corpus callosum agenesis, thalami fusion, facial dysmorphy including hypotelorism, median 
cleft lip and palate, and associated malformations including abnormal lung lobulation. 
Patient 2: The first pregnancy of a 35 year-old woman was terminated at week 21 of gestation 
for major hydrocephalus and spina bifida observed in the female foetus. Anatomopathological 
examination revealed that the foetus had multiple congenital anomalies including alobar HPE, 
facial dysmorphism (bilateral microphthalmia, severe hypotelorism, single nostril, maxillary 
hypoplasia) and lumbar rachischisis associated with intrauterine growth restriction. 
Patient 3: The first pregnancy in this family was terminated for HPE, but unfortunately no 
sample for this foetus was available. The two other brothers were diagnosed with microforms. 
They both share some common features: developmental delay, speech delay, behaviour 
disorder and clinical examination revealed eyes-squint and dimples. The elder brother 
underwent surgery for ventricular septal defect and patent ductus arteriosus. In both cases, 
brain MRI showed enlarged ventricles and callosal dysgenesis. The younger brother had a 
posterior fossa arachnoids cyst or a small cerebellum, and a primitive gyral pattern in frontal 
and left parietal lobe. These cases will be referred to hereafter as patient 3. 
Patient 4: The index case is a newborn girl first diagnosed with hydrocephalus. 
Complementary exams confirmed that she had in fact an alobar form of HPE.  
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Patient 5: This boy was born with non characteristic facial features and absence of corpus 
callosum. He presented mental retardation and feeding intolerance. Semi lobar HPE was 
confirmed by MRI. The DLL1 gene in this patient was sequenced. 
 
Array-CGH: 
Oligonucleotide array-CGH was performed using the Agilent Human Genome CGH 
microarray (Agilent Technologies, Santa Clara, CA, USA). Depending on the patient 44K, 
105K or 244K oligonucleotides arrays were used, as previously described (17). Microarrays 
were scanned using the Agilent scanner G2565BA. Images were extracted using Agilent 
Feature Extraction software and data were analysed with Agilent DNA Analytics and Nexus 
Copy Number softwares to identify chromosome aberrations. Reference genomic DNA was 
from single male or female individuals. 
 
Gene prioritization  
We attempted to identify candidate genes using a prioritization software, Endeavour (20). 
Endeavour uses a variety of different types of data to prioritize a set of genes based on their 
similarities with known candidate genes considered as training genes. These data include 
those from the literature, functional annotation (GeneOntology), and those concerning 
microarray expression, protein domains (InterPro and Motif) and Disease Probabilities (59). 
The software provides an overall ranking by combining the rankings from each category. 
Here, we used the known HPE genes as a training set (4). 
 
Roller-tube culture and chemical inhibition in chick 
Fertile hens eggs were incubated in a humidified room at 38°C. The Embryos were staged 
according to Hamburger and Hamilton (60) (Hamburger and Hamilton, 1992) and were 
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collected at stage 4 (HH4) and cultured as described (61). Folded and sealed embryos along 
the longitudinal axis were transferred to 5ml plastic bottles containing 500!l of Liebovitz 
medium. The bottles were placed on a roller apparatus rotating at 30revs/minute, inclined at 
an angle of about 10 degrees in a 38°C incubator. Development was then allowed to proceed 
for 24 hours. 
Loss of function experiments were performed with the following compounds: cyclopamine 
(Sigma) dissolved at 1mg/ml stock in 2-hydroxypropyl-ß-cyclodextrin (HBC, Sigma); 
SU5402 (Calbiochem), dissolved in 25 mM stock in DMSO. Embryos were treated with 
cyclopamine or SU5402 added to the culture medium continuously from the gastrula stage 
(HH4). Control embryos were treated with DMSO. 
 
Section and whole-mount in situ hybridization 
Whole-mount in situ hybridization was performed with chicken embryos using anti-sense 
digoxigenin-labeled riboprobes as previously described (62). For in situ hybridization with 
paraffin sections, embryos were fixed by 4% paraformaldehyde in PBS (1h, 4°C) and 
embedded in paraffin wax. Section 7 !m thick were cut, placed on slides and rehydrated in 
water: 120!l of the RNA probes (diluted 1/100 in the hybridization buffer) was applied to 
each slide. Plasmid carrying chick Fgf8 (EcorI-T7; gift of Sophie Creuzet) and chick Dll1 
(NotI-T3; gift of Frank Schubert) were used as templates to generate antisense riboprobes. 
 
Sequencing 
All patient and control samples were collected after obtaining informed consent according to 
the guidelines of our institutional review boards. The exons of the DLL1 gene were amplified 
by PCR and analysed by direct sequencing using the BigDye! Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, CA, USA) and the ABI Prism 3130 Genetic Analyzer. 
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The gene mutation nomenclature used in this article follows the recommendations of den 
Dunnen and Antonarakis (2001) (63).  
The patients 1, 2, 3 and 5 described in this paper were tested for mutations and deletions in 
SHH, ZIC2, SIX3, TGIF and DLL1 but none of them had anomalies in these genes. 
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FIGURE LEGENDS 
 
Figure 1: Fine mapping of chromosome aberrations in 6q25.3-6q27.  
Four deletions (red bars) were identified in HPE cases.  
 
Figure 2: Dll1 mutation in a HPE case 
(A) Partial DLL1 reference-sequence-read traces and corresponding traces of deletion as 
identified in patient 5. A heterozygous 3 bp-deletion implicating two codons (yellow box, 
NM_005618.3:c.1802_1804del) was identified in exon 9. This mutation leads to the 
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substitution of two amino-acids (aspartic acid and isoleucine) by one valine (grey box; 
p.Asp601_Ile602delinsVal). (B) Conservation of deleted DLL1 amino acids residues in 
several tetrapod and fish lineages (red bracket). The deletion occurs within an ubiquitination 
sites (ub); prediction of ubiquination sites is based on the preference for acidic residues 
adjacent to the target lysine (64). 
 
Figure 3: Expression of chick Dll1 and comparison with Fgf8 expression between stage 
HH5+ and HH13 in the brain region. (a-f) ventral (i) lateral views. In situ hybridization 
analysis of Dll1 (a,c-e, g,i) and Fgf8 (b,f,h) in whole chick embryos. (a) Early neural fold 
stage chick embryo, expression is in the posterior mesoderm and primitive streak. Note the 
absence of Dll1 transcripts from the Hensen’s Node (HN). Expression is first detected in the 
Head Fold (HF). (b) Note the absence of Fgf8 transcripts from the head fold at this stage. The 
asterix marks the anterior region at Head Fold stage (HH5+) from which Fg8 transcripts are 
absent. (c,d) Dll1 is expressed in the anterior neuropore of the head process. (e,i) At stage 
HH11+ and HH13, Dll1 is expressed in the presumptive telencephalon (T). (g,h) In situ 
hybridization with digoxigenin-labelled Dll1 or Fgf8 antisense probes on frontal histological 
sections at HH11+. The histological sections presented are consecutive sections. Note that 
Dll1 and Fgf8 are both expressed in the surface ectoderm and neurectoderm. O, Optic vesicle; 
PM, Presomitic Mesoderm; I, Isthmus; SE, Surface Ectoderm.  
 
Figure 4: Down-regulation of Dll1 in embryos treated with the FGF inhibitor SU5402 
but not those treated with cyclopamine. Whole-mount in situ hybridization of HH12 
cultured embryos. Embryos are viewed laterally. (a) Dll1 expression in control embryos, 
DMSO (control) treatment has no detectable effect on the embryo. The Dll1 signal is detected 
in ventral telencephalon (T) and presomitic mesoderm (PM). (b) High concentration of 
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SU5402 (10!M) caused severe telencephalic abnormality and downregulation of Dll1. (c) A 
lower concentration of SU5402 affected telencephalon morphogenesis less severely, but Dll1 
is still abolished or significantly reduced in the telencephalon. (d) Treatment of embryos with 
cyclopamine did not inhibited Dll1 expression. 
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Table 1: Major clinical features of individuals with deletions of 6qter and summary of 
the breakpoints. 
Patient HPE type Gender Array Cytogenetic 
bands 
Minimal 
deletion 
(hg18) 
Size 
(Mb) 
1 Semilobar F (foetus) 44k 6q24-6qter 155,166,802-
170,899,992 
15,7 
2 Alobar F (Foetus) 44k del6q25-6qter 158,361,721-
170,899,992 
12,3 
3 Microform M (newborn) 244k Del6q26-6qter 165,7767853-
170,899,992 
5,2 
4 Alobar F (newborn) 105k Del6q27-6qter 168,690,655-
170,899,992 
2,2 
 
 
Table 2: List of the 14 genes located in the 2.2 Mb deleted region 
Genes Name Position OMIM Pathology 
SMOC2 
SPARC related molecular Calcium 
binding 2 
168584880-
168810596 
607223 COPD susceptibility 
THBS2 Thrombospondin 2 
169357800-
169396062 
188061 Lumber disc herniation 
WDR27 WD repeat domain 27 
169811555-
169844084 
None None 
C6orf120 
Chromosome 6 open reading frame 
120 
169844182-
169848327 
None None 
PHF10 PHD finger protein 10 
169845926-
169865909 
613069 None 
TCTE3 
T-complex-associated-testis-
expressed 3 
169882140-
169893563 
186977 None 
C6orf70 
Chromosome 6 open reading frame 
70 
169895885-
169923542 
None None 
C6orf122 
Chromosome 6 open reading frame 
122 
169930811-
169940846 
None None 
C6orf208 
Chromosome 6 open reading frame 
208 
169932342-
169943796 
None None 
DLL1 
Delta-like protein 1 precursor 
(Drosophila Delta homolog 1) 
170591294-
170599697 
606582 
 
None 
FAM120B 
Family with sequence similarity 
120B 
170457769-
170556162 
612266 None 
PSMB1 
Proteasome (prosome, macropain) 
subunit, beta type, 1 
170686134-
170704312 
602017 None 
TBP TATA box binding protein 
170705396-
170723872 
600075 
Spinocerebelar ataxia, Parkinson 
disease, Huntington disease like 4 
PDCD2 Programmed cell death 2 
170732762-
170735673 
600866 Lymphomas 
None: no link to human disease identify by screening various genetic databases and literature. 
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